Results 21 to 30 of about 8,071 (195)

Phenotypical statin‐associated immune‐mediated necrotizing myositis with histological features of inclusion body myositis

open access: yesRheumatology & Autoimmunity, 2023
Introduction Statin‐associated immune‐mediated necrotizing myositis (IMNM) is a rare but distinct idiopathic inflammatory myopathy (IIM) that requires early recognition and intervention to prevent irreversible muscle damage. It is typically characterized
Nicole Daver, Sara Tonini
doaj   +1 more source

Inclusion body myositis: Update on the diagnostic and therapeutic landscape

open access: yesFrontiers in Neurology, 2022
Inclusion body myositis (IBM) is a progressive muscle disease affecting patients over the age of 40, with distinctive clinical and histopathological features. The typical clinical phenotype is characterized by prominent involvement of deep finger flexors
Elie Naddaf
doaj   +1 more source

Pembrolizumab on pre-existing inclusion body myositis: a case report

open access: yesBMC Rheumatology, 2020
Background Cases of exacerbation of pre-existing neuromuscular diseases induced by immune checkpoint inhibitors (ICIs) have rarely been reported because patients with autoimmune diseases have generally been excluded from ICI therapy due to the increased ...
Naohiro Uchio   +9 more
doaj   +1 more source

Polymyositis and dermatomyositis: Disease spectrum and classification

open access: yesIndian Journal of Dermatology, 2012
Muscle inflammation and weakness are the key features of idiopathic inflammatory myopathies (IIMs). In addition IIMs are frequently associated with cutaneous and pulmonary involvement. In clinical practice the three common inflammatory myopathies we come
Siba P Raychaudhuri, Anupam Mitra
doaj   +1 more source

Inclusion-Body Myositis Associated with Alzheimer’s Disease

open access: yesCase Reports in Medicine, 2013
Sporadic inclusion-body myositis (s-IBM) is a myopathy that is characterized by progressive weakness and muscle pathology demonstrating inflammation and rimmed vacuoles.
Danijela Levacic   +4 more
doaj   +1 more source

Inclusion body myositis – pathomechanism and lessons from genetics

open access: yesOpen Medicine, 2015
Inclusion body myositis is a rare, late-onset myopathy. Both inflammatory and myodegenerative features play an important role in their pathogenesis.
Murnyák Balázs   +8 more
doaj   +1 more source

Chemoenzymatic Radiosynthesis of a Gluconate Transporter‐Targeted In Vivo Bacterial Sensor From Clinical [18F]FDG

open access: yesAngewandte Chemie, EarlyView.
An efficient radiosynthesis of fluorine‐18 labeled gluconic acid ([18F]FGA) was developed using two readily available materials, 2‐deoxy‐2‐[18F]fluoro‐D‐glucose ([18F]FDG) and glucose oxidase. [18F]FGA is highly specific for bacterial gluconate metabolism mediated by gluconate permease (GntP) and gluconate kinase (GntK), with rapid clearance, low off ...
Sang Hee Lee   +7 more
wiley   +2 more sources

Increased Cardiac Troponin T May Be a Marker of Worsening Skeletal Myopathy in Inclusion Body Myositis: A Case Report

open access: yesCardiology Discovery
. Previous studies have reported elevated cardiac troponin T (cTnT) in patients with inclusion body myositis due to skeletal myopathy. Although the trends of cTnT have been reported in some cases, the onset of elevation has barely been reported.
Zhiqing Fu, Xiujin Zhang, Hanjia Gao
doaj   +1 more source

Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis

open access: yesFrontiers in Immunology, 2019
Objective: Sporadic Inclusion Body Myositis (sIBM) is an inflammatory myopathy (IIM) without a specific diagnostic biomarker until autoantibodies to the cytosolic 5′-nucleotidase 1A (NT5c1A/Mup44) were reported.
Adam Amlani   +11 more
doaj   +1 more source

Update in inclusion body myositis [PDF]

open access: yesCurrent Opinion in Rheumatology, 2013
The purpose of this study is to review recent scientific advances relating to the natural history, cause, treatment and serum and imaging biomarkers of inclusion body myositis (IBM).Several theories regarding the aetiopathogenesis of IBM are being explored and new therapeutic approaches are being investigated. New diagnostic criteria have been proposed,
Machado, P, Brady, S, Hanna, MG
openaire   +3 more sources

Home - About - Disclaimer - Privacy